Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

Anat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, Gil Harari, David Magalashvili, Polina Sonis, Mark Dolev, Shay Menascu, Shlomo Flechter, Rina Falb, Michael Gurevich

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
JournalTherapeutic Advances in Neurological Disorders
Volume14
DOIs
StatePublished - 2021
Externally publishedYes

Keywords

  • cladrivine
  • COVID-19
  • finfolimod
  • mRNA vaccine
  • multiple sclerosis
  • ocrelizumab

ASJC Scopus subject areas

  • Pharmacology
  • Neurology
  • Clinical Neurology

Cite this